JP2018531280A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531280A5
JP2018531280A5 JP2018529503A JP2018529503A JP2018531280A5 JP 2018531280 A5 JP2018531280 A5 JP 2018531280A5 JP 2018529503 A JP2018529503 A JP 2018529503A JP 2018529503 A JP2018529503 A JP 2018529503A JP 2018531280 A5 JP2018531280 A5 JP 2018531280A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
appendix
salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018529503A
Other languages
English (en)
Japanese (ja)
Other versions
JP6880023B2 (ja
JP2018531280A (ja
JP2018531280A6 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/048643 external-priority patent/WO2017035331A1/en
Publication of JP2018531280A publication Critical patent/JP2018531280A/ja
Publication of JP2018531280A6 publication Critical patent/JP2018531280A6/ja
Publication of JP2018531280A5 publication Critical patent/JP2018531280A5/ja
Priority to JP2021077099A priority Critical patent/JP7134294B2/ja
Application granted granted Critical
Publication of JP6880023B2 publication Critical patent/JP6880023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018529503A 2015-08-25 2016-08-25 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用 Active JP6880023B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021077099A JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ-グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209624P 2015-08-25 2015-08-25
US62/209,624 2015-08-25
PCT/US2016/048643 WO2017035331A1 (en) 2015-08-25 2016-08-25 PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021077099A Division JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ-グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Publications (4)

Publication Number Publication Date
JP2018531280A JP2018531280A (ja) 2018-10-25
JP2018531280A6 JP2018531280A6 (ja) 2018-12-13
JP2018531280A5 true JP2018531280A5 (enExample) 2019-10-03
JP6880023B2 JP6880023B2 (ja) 2021-06-02

Family

ID=58100994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018529503A Active JP6880023B2 (ja) 2015-08-25 2016-08-25 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
JP2021077099A Active JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ-グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021077099A Active JP7134294B2 (ja) 2015-08-25 2021-04-30 改善された特性を有するβ-グアニジノプロピオン酸の薬学的に許容される塩及びその使用

Country Status (16)

Country Link
US (4) US20170056352A1 (enExample)
EP (1) EP3340973B1 (enExample)
JP (2) JP6880023B2 (enExample)
KR (1) KR102707964B1 (enExample)
CN (2) CN114057611A (enExample)
AU (1) AU2016311368B2 (enExample)
CA (1) CA2996520C (enExample)
DK (1) DK3340973T3 (enExample)
ES (1) ES2843561T3 (enExample)
HR (1) HRP20210044T1 (enExample)
HU (1) HUE053963T2 (enExample)
PL (1) PL3340973T3 (enExample)
PT (1) PT3340973T (enExample)
RS (1) RS61804B1 (enExample)
SI (1) SI3340973T1 (enExample)
WO (1) WO2017035331A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168465A1 (en) 2014-04-30 2015-11-05 Rgenix, Inc. Inhibitors of creatine transport and uses thereof
WO2016100619A2 (en) * 2014-12-17 2016-06-23 Rgenix, Inc. Treatment and diagnosis of cancer
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018160178A1 (en) * 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
JP2023505687A (ja) * 2019-12-11 2023-02-10 インスピルナ,インコーポレーテッド 癌の処置方法
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ,インコーポレーテッド 金属塩及びその使用
KR102615692B1 (ko) * 2021-10-13 2023-12-19 주식회사 휴엔켐 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물
US20250270471A1 (en) * 2022-04-21 2025-08-28 Merck Sharp & Dohme Llc Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts
KR102822799B1 (ko) 2022-11-09 2025-06-20 충남대학교산학협력단 베타-구아니디노프로피온산을 포함하는 장내 미생물 개선용 조성물

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA101653A (en) 1906-08-30 1906-10-23 Herman Besser Mould
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
US3933797A (en) * 1972-02-22 1976-01-20 Pfizer Inc. 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS
US3972872A (en) 1974-09-23 1976-08-03 Pfizer Inc. 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids
EP0260118B1 (en) 1986-09-10 1991-12-04 Syntex (U.S.A.) Inc. Selective amidination of diamines
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
CA2028593C (en) * 1989-10-31 2007-08-21 Douglas R. Brandt Stabilized enzyme compositions
DE4334639A1 (de) 1993-10-11 1995-04-13 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten
US5994577A (en) 1994-11-23 1999-11-30 Larsen; Scott D. Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
DE793646T1 (de) 1994-11-23 1999-12-30 Pharmacia & Upjohn Co., Kalamazoo Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
JP3745439B2 (ja) 1995-07-06 2006-02-15 花王株式会社 皮膚外用剤
TW453881B (en) 1995-10-16 2001-09-11 Kao Corp Cosmetic composition comprising amide derivatives
JPH09202710A (ja) * 1995-11-20 1997-08-05 Kao Corp しわ改善剤
AU3117497A (en) 1996-05-21 1997-12-09 Pharmacia & Upjohn Company Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
JP4317599B2 (ja) 1996-06-26 2009-08-19 武田薬品工業株式会社 徐放性製剤
EP1093370B1 (en) 1998-06-30 2006-02-22 Takeda Pharmaceutical Company Limited Pharmaceutical composition for the treatment of diabetes
US6605115B1 (en) 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
EP1656945A1 (en) 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmaceutical composition comprising oligoarginine
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US20020082448A1 (en) 1999-11-08 2002-06-27 The Upjohn Company Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
WO2003013574A1 (en) 2001-08-08 2003-02-20 Merck & Co., Inc. Melanin-concentrating hormone antagonists
JP2005518346A (ja) 2001-11-07 2005-06-23 メディカル リサーチ カウンセル ドパミン作動性ニューロンの調節
JP2005527491A (ja) 2002-01-09 2005-09-15 メルク エンド カムパニー インコーポレーテッド 選択的メラニン凝集ホルモンタイプ−1受容体アゴニスト
WO2003101402A2 (en) 2002-06-04 2003-12-11 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
US20120245211A1 (en) 2002-06-04 2012-09-27 Children's Hospital Medical Center Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism
GB0302882D0 (en) 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
JP4865251B2 (ja) 2005-05-09 2012-02-01 株式会社 資生堂 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物
RU2422049C2 (ru) 2005-08-02 2011-06-27 Альцхем Тростберг Гмбх Жидкая композиция, основанная на компоненте гуанидинуксусной кислоты
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
US7776917B2 (en) 2006-12-11 2010-08-17 Mickle Travis C Non-standard amino acid conjugates of amphetamine and processes for making and using the same
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
EP2109465B1 (en) 2007-02-08 2012-04-11 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
WO2009033130A1 (en) 2007-09-07 2009-03-12 Gencia Corporation Mitochondrial compositions and uses thereof
WO2009098142A1 (en) 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
FR2940077B1 (fr) 2008-12-19 2012-07-20 Oreal Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante.
FR2940104B1 (fr) 2008-12-19 2011-08-19 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin
US7927381B2 (en) 2008-12-19 2011-04-19 L'oreal S.A. Process for lightening or lightening direct dyeing or oxidation dyeing in the presence of an aqueous composition comprising at least one fatty substance, and device
JP5866137B2 (ja) 2009-04-30 2016-02-17 ロレアル アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および/または着色ならびに装置
WO2011031308A1 (en) * 2009-09-09 2011-03-17 Cytokinetics, Incorporated Novel combinations
CN102573888A (zh) 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
FR2954160B1 (fr) 2009-12-22 2012-03-30 Oreal Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
DE102010012199A1 (de) 2010-03-19 2011-09-22 Fresenius Medical Care Deutschland Gmbh Molekular geprägte Polymere für die Eliminierung von Metaboliten
FR2958161B1 (fr) 2010-04-02 2012-04-27 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin
SI2558577T1 (sl) 2010-04-16 2019-05-31 Nuevolution A/S Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
EP2560490A1 (en) 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
CA2795222A1 (en) 2010-04-21 2011-10-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
WO2011143534A1 (en) 2010-05-13 2011-11-17 The Mclean Hospital Corporation Methods for the treatment of psychiatric disorders
EP2399885A1 (en) 2010-06-22 2011-12-28 Ulrich Dietz Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification
WO2012024611A1 (en) 2010-08-20 2012-02-23 Natural Alternatives International, Inc. Methods of treating sarcopenia and frailty
WO2012047630A2 (en) 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US8765115B2 (en) 2010-12-01 2014-07-01 National Institute of Agrobiological Scienses Method of treatment of gastrointestinal disorders with IL-10
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
WO2012122412A2 (en) 2011-03-09 2012-09-13 Signature Therapeutics, Inc. Compositions for reducing risk of adverse events caused by drug-drug interactions
EP2683394B1 (en) 2011-03-09 2021-01-06 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012138214A1 (en) 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102850242A (zh) * 2011-06-27 2013-01-02 天津天成制药有限公司 胍基丙酸硝酸盐的制备方法
US8427223B2 (en) 2011-07-19 2013-04-23 Lsi Corporation Voltage level translator circuit for reducing jitter
KR20180069934A (ko) 2011-07-28 2018-06-25 켐팜 인코포레이티드 메틸페니데이트 프로드러그, 이의 제조 방법 및 사용 방법
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
FR2983407B1 (fr) 2011-12-06 2014-01-03 Oreal Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
EP2914344B1 (en) * 2012-10-31 2020-01-15 The Rockefeller University Treatment of metastatic colon cancer
FR2997846B1 (fr) 2012-11-09 2023-10-20 Oreal Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition
WO2014138492A1 (en) 2013-03-08 2014-09-12 Solan, LLC Methods for fabricating graphite-based structures and devices made therefrom
CN103288685B (zh) * 2013-07-03 2015-02-18 郭礼强 一种3-胍基丙酸的制备方法
US20170056352A1 (en) * 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Similar Documents

Publication Publication Date Title
JP2021530565A5 (enExample)
JP2015512942A5 (enExample)
KR20120059540A (ko) C-met 조절제를 사용하는 방법
JP2016528179A5 (enExample)
JP2013503134A5 (enExample)
TW200808726A (en) Novel polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
JP2009535340A5 (enExample)
JP2014524476A5 (enExample)
KR102612379B1 (ko) 벤조푸란 유도체 자유 염기의 결정 및 제조 방법
JP2020521732A5 (enExample)
RU2017142958A (ru) Кристаллы азабициклического соединения
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты
JP2019516749A5 (enExample)
JP2018503649A5 (enExample)
RU2018103172A (ru) Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона
JP2016505071A5 (enExample)
JP2021501766A5 (enExample)
JP2015516425A5 (enExample)
RU2013120549A (ru) Новые кристаллические формы натриевой соли(4-{4-[5-(6-трифторметил-пиридин-3-иламино) пиридин-2-ил] фенил} циклогексил) уксусной кислоты
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
JP2011515421A5 (enExample)
CA3140231A1 (en) 3-aryloxyl-3-five-membered heteroaryl-propylamine compound, and crystal form and use thereof
JP2019509295A (ja) レチノイン酸系化合物、その製造方法、中間体及び応用
RU2015113277A (ru) Кристаллическтие соединения